The identification of SCN5A as an important disease gene [53] in BrS suggested that the syndrome was a monogenetic disorder, similar to LQTS
Licensed compounding pharmacies may be able to once again operate within a defined regulatory framework to prepare these peptides, bringing them back into a setting where quality, oversight, and traceability are central.[6] Patients can access therapies within a system designed to protect them
Methods 3 , 281286 (2006)
This review highlights epidemiology, risk factors, genetics, pathogenesis, clinical manifestations, diagnostic methods, epigenetic mechanisms, and recent therapeutic advances
6,7 Reliable strategies for managing ME/CFS have historically been limited